With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

“We are in a period of great momentum and execution at Structure Therapeutics (GPCR), having begun ... profile of GSBR-1290 as a potential best-in-class oral small molecule GLP-1 receptor agonist. We ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar ...

Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

We actually call these GLP-1 patients GLP-1 orphans ... we really evaluated the entire structure across all departments and we looked at ways to gain efficiency and work towards profitability at the ...